Physician profile
Vicente Lim
NPI 1275529356
$13,499.81
in general payments reported to CMS, 2019-2025
15 companies · $2,174 in 2025
The $2,174 reported for 2025 was more than what 90% of Psychiatry providers received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,618 · 2020: $1,574 · 2021: $2,302 · 2022: $1,598 · 2023: $2,076 · 2024: $2,157 · 2025: $2,174.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,195 · Education: $213.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,194.55 |
| Education | $212.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teva Pharmaceuticals USA, INC. | $2,420.83 | 2019-2025 | Uzedy, Austedo Xr, Austedo |
| Neurocrine Biosciences, INC. | $1,895.97 | 2019-2025 | Ingrezza |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $1,320.90 | 2020-2025 | Caplyta |
| Otsuka America Pharmaceutical, INC. | $1,240.36 | 2019-2025 | Abilify Maintena, Rexulti, Abilify Asimtufii |
| Alkermes, INC. | $1,099.53 | 2019-2025 | Aristada, Lybalvi |
| Abbvie INC. | $1,080.33 | 2021-2025 | |
| Sunovion Pharmaceuticals INC. | $967.73 | 2019-2022 | |
| Janssen Pharmaceuticals, INC | $966.26 | 2019-2025 | Invega Sustenna, Invega Trinza |
| Lundbeck LLC | $723.45 | 2020-2025 | Rexulti |
| Vanda Pharmaceuticals INC. | $530.43 | 2019-2024 | Fanapt, Hetlioz |
| Indivior INC. | $525.39 | 2019-2024 | Perseris |
| Allergan, INC. | $342.74 | 2019-2020 | |
| Luye Pharma (USA) LTD. | $190.90 | 2025 | Erzofri Extended-Release |
| E.R. Squibb & Sons, L.L.C. | $181.19 | 2025 | Cobenfy |
| Avanir Pharmaceuticals, INC. | $13.80 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Vicente Lim listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.